LVTX241115C5000
- 0.05
- 0.000.00%
LAVA Therapeutics Newsroom
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target
Jefferies Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy Rating
JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
Buy Rating Affirmed: LAVA Therapeutics' Financial Stability and Promising Clinical Pipeline
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
LAVA Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), LAVA Therapeutics (LVTX) and Aura Biosciences Inc (AURA)
Analysts Offer Insights on Healthcare Companies: LAVA Therapeutics (LVTX), Acumen Pharmaceuticals (ABOS) and Advanced Medical Solutions (GB:AMS)
Buy Rating Affirmed for LAVA Therapeutics Amid Promising T-Cell Cancer Therapy Trials and Strong Financials
Strong Buy Rating for LAVA Therapeutics on Promising Clinical and Financial Outlook
LAVA Therapeutics Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)
Strong Buy Rating for LAVA Therapeutics Amid Strategic Partnerships and Promising Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and LAVA Therapeutics (LVTX)
Promising Financial Performance and Ongoing Clinical Trials Bolster LAVA Therapeutics' Buy Rating: A Comprehensive Analysis
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
LAVA Therapeutics Analyst Ratings
JMP Securities Reiterates Market Outperform on LAVA Therapeutics, Maintains $6 Price Target